Pharma & Bio
Lifestyle
Hugel, Inc. Bought Time, Hans Bought a Sales Network... The Real Story Behind the Skinbooster Collaboration
Hugel, Inc. and HANS BIOMED CORPORATION have begun jointly marketing “CellREDM,” a human tissue-based skin booster. While this appears to be a distribution agreement on the surface, analysts view it a…
Technology
Peptron Plummets as Lilly Hopes Fade; Nature Cell and BL Pharmtech Hit Daily Limit-Up [K-Bio Pulse]
On July 9, South Korean pharmaceutical and biotech stocks saw sharply divergent movements, with Nature Cell and BL Pharmtech both hitting the daily upper limit, while Peptron tumbled to the lower limi…
Technology
Peptron, Inc. Hits After-Hours 'Lower Circuit' as Lilly Hopes Fade… NATURECELL CO.,LTD. and BL Pharmtech Rise [Bio Spotlight]
On the 9th, the domestic pharmaceutical and biotech stock market saw mixed results across individual stocks. While Peptron, Inc. hit the daily price limit down in after-hours trading, NATURECELL CO.,L…
Technology
'Generic Drug Inspection' Holds Up Ribozeranib… Even HLB INC. Was Unaware
It has been confirmed that the reason behind HLB INC.(028300)’s new liver cancer drug, Riboceranib, receiving its third Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) …
Business·Industry
Peptron, Inc. Emphasized "Smooth Sailing" with Lilly, but... Excluded from Joint Research After Mounjaro and MTA
Peptron, Inc.(087010), following its official statement that its joint research with Eli Lilly is proceeding normally, issued a revised notice around 12:00 p.m. today explaining that tirzepatide is in…
Technology
Kim Deok-kyu, CEO of GeronCellVein: "We’re Revolutionizing the PDRN Market with Low-Temperature Extraction Technology... Aiming for an IPO Next Year"
“Extraction at high temperatures inevitably causes DNA damage. We have dramatically improved safety by maintaining a consistent molecular weight—like a fingerprint—through low-temperature extraction a…
Lifestyle
Psomagen, Inc. Clears the ‘Most Demanding’ New York Clinical Testing Hurdle… Begins Full-Scale Push into the Genomic Diagnostics Market
Psomagen, Inc.(950200)has secured certification from the New York State Department of Health, which is considered a key gateway to the U.S. genomic diagnostics market. This achievement is seen as layi…
Technology
Antrogen Slides on Japan Fears, Hanmi Science Gains [K-Bio Pulse]
South Korean biopharmaceutical stocks moved in opposite directions on Tuesday, with Antrogen tumbling to the daily limit amid concerns over the commercial potential of its regenerative medicine produc…
Technology
ANTEROGEN CO., LTD. Hits ‘Daily Lower Limit’; “25 Patients in Japan Is an Initial Estimate”… Hanmi Science Soars Amid ‘Control Dispute’ [Bio Spotlight]
On the 8th, in the domestic pharmaceutical and biotech stock market, ANTEROGEN CO., LTD.(065660)plummeted to its daily price limit amid concerns over its market potential in Japan, while Hanmi Science…
Technology
With Latuda’s Indications Expanding and Synergies with Union Pharmaceutical… Will BukwangPharmaceutical’s Enterprise Value Be Reevaluated?
BukwangPharmaceutical(003000)is kicking off a revaluation of its corporate value, driven by the expanded indication for its key new drug “Latuda” for depression and the synergies from its acquisition …